Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CDK9 | P50750 | 3/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | CCND1 | P24385 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.31 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243313 | 0.88 | CCNT1 (0.34) | CCNT1CDK2CDK9CCNA1CDK1 | |
| SCHEMBL14242903 | 0.81 | CSNK2B (0.32) | — | |
| SCHEMBL14242524 | 0.81 | CCNT1 (0.34) | CCNT1CDK2CDK9CCNA1CDK1 | |
| SCHEMBL14242530 | 0.77 | PAX8 (0.37) | PAX8IRAK4 | |
| SCHEMBL14242529 | 0.76 | PDE10A (0.44) | PAX8 | |
| SCHEMBL14243308 | 0.70 | CSNK2B (0.31) | — | |
| SCHEMBL2027726 | 0.65 | PDE10A (0.40) | CCNT1CDK2CDK9CCNA1GPR119 | |
| SCHEMBL14242607 | 0.65 | USP30 (0.36) | CCNT1CDK2CDK9CCNA1CDK1 | |
| SCHEMBL17655257 | 0.64 | HTR1D (0.33) | CCNT1CDK9GPR119 | |
| SCHEMBL21248469 | 0.64 | BRD4 (0.38) | PAX8IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170827-A2 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |